Pro-inflammatory cytokines are critical factors in type 2 diabetes-associated atherosclerosis. We aim to analyze in hypertensive type 2 diabetic patients the serum concentrations and the mRNA expression levels in peripheral blood mononuclear cells (PBMC) of the pro-inflammatory cytokine tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6), as well as to evaluate the effect of amlodipine administration. Twenty-one hypertensive diabetic patients and 10 healthy non-diabetic controls were included in the study. Serum levels of cytokines were measured by chemiluminescent immunometric assay, and mRNA expression levels by RT-PCR. The mean serum concentrations of TNF-a and IL-6 in diabetic patients showed a 6.1-fold and 2.9-fold increase with respect to non-diabetic control subjects, respectively (p<O.OOOI). Likewise, there was a 3.3-and a 4-fold increase in the PBMC mRNA expression level of TNF-a and IL-6 (p<O.OOOI) in diabetic subjects. After amlodipine administration, a significant decrease (p<O.OI) was observed in the serum TNF-a and IL-6Ievels. In addition, pre-treatment mRNA expression of TNF-a and IL-6 also decreased, with a mean percent reduction of 26% (p<O.OI) and 25% (p<O.OOI), respectively. In conclusion, serum concentrations and PBMC mRNA expression levels of TNF-a and IL-6 are significantly elevated in hypertensive type 2 diabetic patients. Administration of amlodipine is associated with a significant reduction of the increased levels of these inflammatory parameters, both at the protein as well as at the transcriptional level. These modulatory effects of amlodipine on proinflammatory cytokine level and expression may be related to its suggested anti-atherosclerotic actions.
Pro-inflammatory cytokines are critical factors in type 2 diabetes-associated atherosclerosis. We aim to analyze in hypertensive type 2 diabetic patients the serum concentrations and the mRNA expression levels in peripheral blood mononuclear cells (PBMC) of the pro-inflammatory cytokine tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6), as well as to evaluate the effect of amlodipine administration. Twenty-one hypertensive diabetic patients and 10 healthy non-diabetic controls were included in the study. Serum levels of cytokines were measured by chemiluminescent immunometric assay, and mRNA expression levels by RT-PCR. The mean serum concentrations of TNF-a and IL-6 in diabetic patients showed a 6.1-fold and 2.9-fold increase with respect to non-diabetic control subjects, respectively (p<O.OOOI). Likewise, there was a 3.3-and a 4-fold increase in the PBMC mRNA expression level of TNF-a and IL-6 (p<O.OOOI) in diabetic subjects. After amlodipine administration, a significant decrease (p<O.OI) was observed in the serum TNF-a and IL-6Ievels. In addition, pre-treatment mRNA expression of TNF-a and IL-6 also decreased, with a mean percent reduction of 26% (p<O.OI) and 25% (p<O.OOI), respectively. In conclusion, serum concentrations and PBMC mRNA expression levels of TNF-a and IL-6 are significantly elevated in hypertensive type 2 diabetic patients. Administration of amlodipine is associated with a significant reduction of the increased levels of these inflammatory parameters, both at the protein as well as at the transcriptional level. These modulatory effects of amlodipine on proinflammatory cytokine level and expression may be related to its suggested anti-atherosclerotic actions.
Arterial hypertension (HYP) and diabetes mellitus, two intimately related diseases, have a critical adverse impact on cardiovascular morbidity and mortality, and represent a major public health problem. These diseases are not only associated with increased mortality in patients with established cardiovascular disease; they also confer a worse prognosis in subjects without cardiovascular symptoms. HYP and diabetes are well-known risk factors for the development of atherosclerotic disease, in tum a major determinant of clinical outcome in hypertensive diabetic subjects.
Nowadays, there is increasing evidence that the pro-atherogenic effects of HYP and diabetes are, at least in part, mediated through inflammatory mechanisms (1) (2) . Accumulating data have highlighted the relationship between inflammation and HYP. It has been suggested that HYP exerts pro-inflammatory actions, with an important role of diverse inflammatory mediators including adhesion molecules, growth factors, chemokines and cytokines. Regarding type 2 diabetes, this illness is now considered an inflammatory cardiovascular disease, with mounting evidence indicating that inflammation is the bridging link between atherosclerosis and type 2 diabetes.
Monocytes and T cells are critical elements in the early stages of atherosclerosis. The activation of these cells results in the release of mediators of inflammation, including tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6),. two of the main pro-inflammatory cytokines that play a pivotal role in the pathogenesis of atherosclerosis (3) (4) . Moreover, clinical studies have demonstrated that these cytokines are independent predictors of cardiovascular events and mortality (5) .
Dihydropiridine-type calcium channel blockers (CCB), in addition to their primary action in lowering blood pressure, may influence a number of cellular processes involved in atherogenesis. In fact, results from basic research and clinical trials indicate that these drugs might have atheroprotective effects (6). Amlodipine, a third-generation of L-type calcium channel-blocker, has shown important pleiotropic properties, including regulation of membrane fluidity and cholesterol deposition, stimulation of nitric oxide production, antioxidative effects, and regulation of matrix deposition (7) . Interestingly, in vitro, in vivo and clinical studies in HYP and heart failure have reported that amlodipine is potentially able to modulate TNF-a and IL-6 production (8) (9) (10) .
Less is known about the serum and gene expression profile of the pro-inflammatory cytokines in hypertensive type 2 diabetic patients and the effect of anti-hypertensive therapy on these variables. The present study was undertaken to analyze in these patients the serum concentrations of TNF-a and IL-6, as well as the mRNA expression levels for these cytokines in peripheral blood mononuclear cells (PBMC), and to evaluate, under usual clinical practice conditions, the potential effect ofamlodipine administration on these parameters.
MATERIALS AND METHODS

Patients
A previous sample size calculation to detect a 25% relative difference in, the change in serum TNF-a concentration in hypertensive diabetic patients after amlodipine administration with an a value of 0.05 and a b value of 0.80 showed a need for a minimum of 17 individuals. Patients were randomly recruited from our diabetic outpatient clinic database according to the inclusion criteria: type 2 diabetes under insulin therapy; non-smokers; uncontrolled HYP (defined as a blood pressure (BP) higher than or equal to 130/80 mmHg); normal renal function, defined as a GFR higher than 60 ml/min (calculated using the Modification of Diet in Renal Disease study equation) (11) ; no medical history of cardiovascular events in the previous six months; and treatment with blockers of the rennin-angiotensin system for at least six months. Finally, 21 type 2 diabetic patients were included in this study. They received amlodipine for 4 months (5 mg daily for six weeks, and then 10 mg/day if blood pressure was higher than 130/80 mmHg). These patients had not been previously treated with CCB, and all of them received acetylsalicylic acid and angiotensinconverting enzyme inhibitors (ACEI) or angiotensin II type I receptor blockers (ARB) at the maximal recommended dosage for more than six months. Apart form blockers of the renin-angiotensin system, they received diuretics, alpha-and/or beta-blockers and moxonidine as antihypertensive therapy. During the study there were no changes in the concomitant medication. The protocol was in accordance with the Declaration of Helsinki and the local committee, and all patients gave informed consent before participating in the study. In addition, 10 healthy controls were also included for comparisons.
Before the definitive inclusion, the possible existence of immunologic diseases, malignancy, and infections was investigated. White blood cell count was lower than I0,000/mm3 in all cases. Determination oftumoral markers including carcino-embryonic antigen, a-fetoprotein, cancer antigen 125, and prostate-specific antigen were negative. Serologic tests for antinuclear antibodies, antibodies, rheumatoid factor, immunoglobulins, and complement were negative or within the normal range. Urine cultures and serology to hepatitis B, hepatitis C, and HIV were also negative.
Study parameters
Body mass index (BMI) was calculated as weight (kg)/height (m'), Arterial BP Was measured by a mercury sphygmomanometer by the same observer with the patient in the sitting position after 5 min of rest. Three readings separated by 2 min were taken, and the average was used for calculation. The first appearance of sound (phase 1) was used to define systolic BP, and the disappearance of sound (phase 5) was used to define diastolic BP.
General biochemical variables and cytokines
Blood samples were drawn from each patient before breakfast in the morning (between 8 and 11 a.m.), after an 8-to l2-h overnight fast. Samples were collected in sterile tubes, centrifuged at 3000 g for 10 min at 4°C, and then stored at -80°C until assayed. The plasma glucose level was measured by an automated enzymatic method. The glycated hemoglobin (HbA1c) concentration was measured by high performance liquid chromatography.
Serum concentrations of TNF-a and IL-6 were measured by a solid-phase, chemiluminescent immunometric assay. The analytical sensitivity for TNF-a was 1.7 pg/ml, and the intra-and interassay coefficients of variability were 3.6% and 4.4%, respectively. Regarding IL-6, the analytical sensitivity was 2 pg/ml, and the intraand interassay coefficients of variability were 6.2% and 7.5%, respectively.
Urinary albumin excretion was determined as the albumin to creatinine ratio (ACR) in the first-voidmorning urine sample, and expressed as mg/g.
Isolation ofPBMC and RNA extraction
PBMC were isolated from whole venous blood (10 ml) collected into heparinated tubes and diluted with an equal volume of PBS. PBMC were isolated by density gradient centrifugation (Ficoll-Paque method). For each sample, two l5-ml centrifuge tubes were used to layer 7 ml of diluted blood onto an equal volume of Ficoll-Hypaque. The suspension was centrifuged for 30 min at 450 g and 20°C. The mononuclear cell layer was removed with manual pipetting, washed twice with PBS, and centrifuged for 10 min at 10°C and 275 g after each wash. Washed cells were resuspended in 1 ml of PBS. For RNA extraction, the PBMC suspension was centrifuged for 3 min at 3,000 g, and the supernatant was discarded. Total RNA was isolated by using TRlreagent (Sigma-Aldrich, Steinheim, Germany) as described in manufacturer's instructions. The concentration and purity of the recovered RNA were established by measuring ultraviolet absorbance at 260 and 280 nm. Total RNA integrity was checked by agarose gel electrophoresis and ethidium bromide staining.
Primers and Real-Time polymerase chain reaction
Expression levels ofTNF-a and IL-6 were analysed by real-time quantitative RT-PCR. The sequence of primers were designed for an annealing temperature of 60°C using Primer 3 software (http://frodo.wi.mit.edulcgi-bin/ primer3/primer3_www.cgi), except from b-actin primers (a housekeeping gene) which also anneals at 60°C. The primers were used for relative quantification of targeted gene expression as follows. For TNF-a: forward primer, 5'-GCCACCACGCTCTTCTGT-3'; reverse primer, 5'-· GGCTACGGGCTTGTCACTC-3'. For IL-6: forward primer, 5'-GTATGAACAGCGATGATGCAC-3'; reverse primer, 5'-GAAACGGAACTCCAGAAGACC-3' . Fluorescein was also added in a final concentration of 1: 100,000 in order to normalize differences in amount of intercalating dyes caused by pippetting errors. RT-PCR amplification was performed on an iCycler iQ Real Time PCR system (BioRad, Hercules, CA, USA) and analyzed with the provided software (iCycler software version 3.0). A three-step run protocol was used: (i) an initial hold of 9 minutes at 95°C to activate Taq polymerase and a fluorescence measurement to normalize the whole plate amount of fluorescein dye, (ii) an amplification and quantification cycle with 45 repeats (denaturation 20 sec at 95°C, annealing 20 sec at 60°C and extension 20 sec at noc with a fluorescence measurement), (iii) a melting curve analysis from 65°C to 95°C to check the specificity of the amplified product. Agarose gel electrophoresis was performed to confirm that there were single-product amplifications without primer dimers. Additionally, all fragments were checked for specificity by direct sequencing of both strands with an ABI PRISM 310 Genetic Analyzer using Big Dye Terminator kit v 3.1 (Applied Biosystems, Foster City, CA, USA). Expression of cytokine mRNA for each sample was then expressed as an arbitrary ratio of the quantity of mRNA to that of -actin.
Statistical analysis
Statistical analyses were conducted using Statistica 7.0 (Statsoft Inc., Tulsa, OK, USA). Results are expressed as mean ± SD. Serum levels of TNF-a and IL-6, as well as expression ratios, were logarithmically transformed for statistical analyses and then back-transformed to their natural units for presentation in tables and figures. Statistical comparisons between hypertensive diabetic patients and control subjects were performed by unpaired Student's t test. Since the lack of a control group 
RESULTS
Data from diabetic patients and healthy controls included in the study are depicted in Table I . Regarding inflammatory parameters, diabetic subjects had significantly higher levels of serum CRP (p<O.OI), TNF-a and IL-6 (p<O.OOOI). The mean serum levels of TNF-a and IL-6 in diabetic patients showed a 6.I-fold and 2.9-fold increase with respect to non-diabetic control subjects, respectively.
The mean levels of~-actin mRNA were similar between groups for each set of PCR reactions, confirming that starting concentrations of cDNA were similar and not subjected to systematic error. The levels of expression of the pro-inflammatory cytokine genes were significantly increased in diabetic patients. The mean mRNA expression levels of TNF-a and IL-6 showed, respectively, a 3.1-fold and 3.4-fold increase (p<O.OOOI) in respect to nondiabetic controls (Fig. I) .
The evolution of the different parameters after amlodipine administration to the 21 hypertensive diabetic patients is depicted in Table II . Both systolic and diastolic BP experienced a significant reduction at the end of the study. The mean decrease in SBP and DBP was 8.7 and 8 mmHg, respectively. Serum concentrations offasting glucose and HbAlc, as well as BMI, did not experience significant variations. After 16 weeks of amlodipine treatment BMf: Body mass index; HbAlc: Glycated haemoglobin; BP: Blood pressure; ACR: Albumin to creatinine ratio; NS: not significant; TNF-a: tumor necrosis factor-a; fL-6: interleukin-6; CRP: C-reactive protein it was possible to detect a significant reduction of inflammatory parameters. The mean percent decrease of serum TNF-a and IL-6 concentrations was 22.5% and 38.4%, respectively (p<0.01). In addition, the pre-treatment mRNA expression levels of these pro-inflammatory cytokines in PBMC also experienced a significant decrease after amlodipine administration, with a mean percent reduction of 26% for TNF-a (p<O.OI) and 25% for IL-6 (p<O.OOI) (Fig. 2) . In spite of this significant decrease, the serum concentrations of CRP (p<0.01), TNF-a and IL-6 (p<O.OOOI), as well as the mRNA expression levels of these cytokines in PBMC (p<0.001), at the end of the study were higher that those observed in control subjects. Multivariate analysis showed that serum concentrations of TNF-a and IL-6 were significantly correlated with CRP (r=0.45, p<0.05; and r=0.51, p<O.OI, respectively). Expression levels of TNF-a in PBMC were related to the serum concentration of this cytokine (r=0.44, p<0.05). No correlation was observed between basal serum cytokine concentrations and SBP or DBP. However, changes in the serum concentration of IL-6 were inversely related to the basal serum levels of this cytokine (r=-0.71, p<O.OOI). Serum concentrations and mRNA expression levels of TNF-a at baseline were inversely related to the change in TNF-a mRNA expression: r=-0.49 (p<0.05), and r=-0.76 (p<0.001), respectively. Likewise, the change in IL-6 mRNA expression was inversely correlated with its basal expression (r=-0.63, p<O.OI). No correlation was found between the changes in the mRNA expression levels of these inflammatory cytokines and the variation of BP.
DISCUSSION
In the present study we investigated the serum concentrations in type in 2 diabetic patients ofTNF-ig. 1. Peripheral blood mononuclear cell mRNA expression levels oftumor necrosis factor-a (TNF-alpha) and interleukin-6 (IL-6) in control subjects and diabetic patients.
greater risk than non-diabetic individuals of developing atherosclerosis' and its complications. Several conditions have been proposed to explain the accelerated atherosclerosis in diabetes, including hyperglycemia, advanced glycation end-products, oxidative stress, dyslipidemia, hyperinsulinemia and genetic variables. In addition, over the past decade overwhelming evidence has accumulated showing a fundamental role of inflammation in mediating the initiation, progression and, ultimately, the complications of atherosclerosis. Therefore, inflammation emerges as an important potential factor in the accelerated atherosclerosis of diabetes. Our study shows that serum concentrations of TNF-a and IL-6 are significantly elevated in diabetic patients. An inflammatory score with CRP, TNF-a and IL-6 has been associated with retinopathy, albuminuria and cardiovascular disease in the EURODIAB study (14) . Importantly, elevated concentrations of these pro-inflammatory cytokines have been independently associated with increased cardiovascular risk and mortality (15) (16) (17) (18) .
Infiltration of monocytes and T cells into the intima of the artery wall is an early hallmark of atherosclerosis, with activation of these cells resulting in humoral and cellular responses that critically contribute to the development and progression of the atherosclerotic lesion (19) . An increased expression of pro-inflammatory cytokines in PBMC has been related to cardiovascular disease. Kostulas et al. (20) demonstrated in a longitudinal study of patients with ischemic stroke an increased expression of inflammatory interleukins, which was significantly correlated with neurological impairment. On the other hand, Akatsu et al. (21) showed an increased mRNA expression of TNFa in circulating leucocytes of patients with acute myocardial infarction. Our results show that, in addition to the elevated serum concentrations of pro-inflammatory cytokines, PBMC from diabetic patients exhibited an inflammatory activation. In respect to control individuals, we noted in diabetic subjects a 3.3-and a 4-fold elevation of the mRNA expression of TNF-a and IL-6 genes, respectively. This overexpression of pro-inflammatory cytokine genes in PBMC might contribute significantly to the higher incidence of macrovascular disease in these patients. = a and IL-6, as well as the mRNA expression levels of these pro-inflammatory cytokines in PBMC. Our findings show that diabetic patients had elevated inflammatory parameters compared with healthy non-diabetic control subjects. Previous studies have demonstrated that type 2 diabetes is associated with a subclinical chronic inflammatory state reflected by elevated concentrations of diverse inflammatory molecules, including pro-inflammatory cytokines (12) (13) .
I-G»nulI ElDidxtes
Classical studies have shown that diabetes mellitus is associated to an increased cardiovascular risk, with diabetic patients having a 2-to 4-fold o.s 2 Fig. 2 . Peripheral blood mononuclear cell mRNA expression levels of tumor necrosis factor-a (TNF-alpha) and interleukin-6 (IL-6) in hypertensive diabetic patients before (Basal) and after 4 months (Final) of amlodipine administration.
Recent studies have shown that anti-hypertensive strategies based on amlodipine have resulted in reduction of incidence of unstable angina, cardiovascular events, need of revascularization in patients with coronary artery disease, stroke and mortality (22) (23) (24) . It was demonstrated that BP reduction was not the only contributor to the decrease in cardiovascular events (25) . In the PREVENT study (22) , amlodipine showed anti-atherosclerotic effects with reduction of carotid intima-media thickness progression, an effect that has been suggested to be related with antioxidant, antiproliferative and antiinflammatory properties.
Concerning these potential anti-inflammatory effects of amlodipine, diverse in vitro investigations have shown an inhibitory action on cytokine production by vascular smooth muscle cells and peripheral blood mononuclear cells (34-36). In addition, in vivo studies have reported that amlodipine reduces the serum concentrations of proinflammatory cytokines in different animal models (28) . These experimental data have been confirmed in clinical trials. The PRAISE Heart Failure Trial showed that amlodipine significantly reduced plasma IL-6 levels in patients with chronic heart failure, although there was not any significant change in plama TNF-a concentrations (5) . However, two recent works show that, along with reduction of IL-6, amlodipine is also able to reduce TNF-a. Salomon et al. (29) showed that amlodipine administration to patients with congestive heart failure caused significant decrease of TNF-a and IL-6 in respect to basal levels by 25% and 30%, respectively. In another study, Ersoy et al. (30) observed that amlodipine therapy in hypertensive type 2 diabetic patients resulted in a 53% significant TNF-a value reduction. In the present study, amlodipine administration was associated with a significant reduction of the serum concentrations of both pro-inflammatory cytokines by approximately 25%. In addition to this effect on serum levels of these cytokines, our findings show that amlodipine is also able to reduce the overexpression of TNF-a and IL-6 genes observed in PBMC from hypertensive diabetic patients.
Two additional aspects of interest need to be considered in the discussion of this study. Firstly, reduction of blood pressure might contribute, at least partially, to the reduction of TNF-a and IL-6. There is growing evidence on the relationship between HYP and inflammation, with elevated blood pressure exerting pro-inflammatory actions. This effect might be mediated by biomechanical forces acting on the vascular endothelial and smooth muscle cells with the subsequent production of inflammatory molecules. Therefore, reduction of blood pressure may be associated with a decrease of the stress on the vascular wall, with modulation of the synthesis of inflammatory molecules, which would contribute to the reduction of the serum levels of inflammatory cytokines. However, reduction of the mRNA expression levels of TNF-a and IL-6 in PBMC is not explained by the decrease of blood pressure, suggesting an effect related to amlodipine administration. Secondly, angiotensin II is now recognized as a true pro-inflammatory cytokine, with stimulating effects favouring inflammation. Therefore, inhibition ofangiotensin II action by ACEI or ARB may potentially associate significant effects on TNF-a and IL-6. All of our patients received ACEI or ARB at the maximal recommended dosage for more than 6 months. Thus, it is very unlikely that the observed effects on TNF-a and IL-6 in patients receiving amlodipine could be related to blockade of renin-angiotensin system.
In conclusion, our study shows that hypertensive type 2 diabetic patients present an inflammatory profile. Systemic levels of the pro-inflammatory cytokines TNF-a and IL-6 are significantly elevated, along with a 3.3-and 4-fold overexpression of TNF-a and IL-6 genes in PBMC, respectively. This systemic inflammatory profile with activation of PBMC could be an important factor in the accelerated atherosclerosis observed in type 2 diabetes mellitus. According to the implications of pro-inflammatory cytokines on the elevated cardiovascular risk of diabetic patients, further studies are necessary to clarify the changes in the TNF-a and IL-6-associated downstream molecules. This may reveal new pathophysiologic implications and show new potential therapeutic targets. In addition, our study shows that amlodipine administration is associated with anti-inflammatory effects modulating TNF-a and IL-6 both at the protein level and at the transcriptional level as well. Since inflammation is a critical factor in type 2 diabetes and its complications, further studies will have to clarify the anti-inflammatory pleiotropic properties of amlodipine in the diabetic patient and their potential benefits on diabetic complications.
